OBD presented a Next Generation Sequencing (NGS) extension of its EpiSwitchTM technology platform. This technological innovation offers an unbiased discovery of EpiSwitchTM biomarkers. The new approach has been validated for melanoma and was supported by the latest results from OBD for the development and cross-validation of the OBD melanoma test.

This novel approach offers an unprecedented scope for the identification and classification of biomarkers for the stratification of the most challenging clinical conditions, while retaining the unique utility of the EpiSwitchTM read-out.

The data was presented within the Epigenetic Session in a talk entitled “Chromatin Loops, Epigenetics & NGS: Data Driving Biomarkers” by the Company CSO, Dr Alexandre Akoulitchev.